Mark Robinson <[email address]>
RE: SleepDrops International Callaghan Funding Grant
2 messages
Tony Vujnovich <[email address]>
7 October 2020 at 16:33
Released
To: Mark Olley <[email address]>
Cc: Mark Robinson <[email address]>
Hi Mark,
I see that you were already dealing directly with Mark Robinson at Callaghan before we met. It would be simpler if
you deal directly with Mark on the grants and other R&D support as he is a specialist in this area.
under the Official Information Act 1982
Regards
Tony Vujnovich
From: Mark Olley <
[email address]>
Sent: Monday, 5 October 2020 10:56 AM
To: Tony Vujnovich <
[email address]>
Subject: RE: SleepDrops International Callaghan Funding Grant
Hi Tony
Could you give me a quick call when you have a chance-
9(2)(a) - Privacy
Im looking for some guidance on starting the application process for clinical trials
Regards
From: Tony Vujnovich [
mailto:[email address]]
Sent: Thursday, 1 October 2020 3:48 PM
To: Mark Olley <[email address]>
Subject: FW: SleepDrops International Callaghan Funding Grant
Hi Mark,
Something I missed, we've got a fair bit of case study and regulatory touchpoint maps available on our HealthTech
Activator website
www.hta.callaghaninnovation.govt.nz
Regards
Tony Vujnovich
Released
From: Tony Vujnovich
Sent: Thursday, 1 October 2020 1:15 PM
To: 'Mark Olley' <
[email address]>
Subject: RE: SleepDrops International Callaghan Funding Grant
Hi Mark,
Further to our meeting regarding Sleepdrops planed R&D and Clinical trials. Attached is a Project Grant template and
a guide to identifying core R&D. To get a better idea of the scope of the R&D and trials can you please draft section
under the Official Information Act 1982
three of the application. This needs to be in technical terms as Callaghan needs to understand the technical
challenges being faced. S3 will also enable be to work out who the relevant experts are at Callaghan.
You were also considering the Innovation IP program, you can learn more at - https://www.
callaghaninnovation.govt.nz/innovation-skills/innovation-ip
The list of Service Providers is on that page
Is there anything I have left out? Please get back to me.
Regards
Tony Vujnovich
From: Mark Olley <
[email address]>
Sent: Wednesday, 30 September 2020 9:05 AM
To: Tony Vujnovich <
[email address]>
Subject: RE: SleepDrops International Callaghan Funding Grant
Hi Tony
I’m just following up next steps to start the application process for a possible Grant for Sleep Drops- Have you any
thoughts since our meeting as to how to proceed? We are very keen to get the Clinical trials underway
Regards
Mark
From: Tony Vujnovich [
mailto:[email address]]
Sent: Tuesday, 22 September 2020 1:47 PM
To: Mark Olley <[email address]>
Subject: RE: SleepDrops International Callaghan Funding Grant
Hi Mark,
Thanks for the information, it’s certainly worth taking the conversation further. Attached is a summary of the Callaghan
Released
Innovation grants, criteria and programs as well as a guide to help identify the projects core R&D.
I look forward to meeting you and Kirsten on Thursday.
Regards
Tony Vujnovich
under the Official Information Act 1982
From: Mark Olley <
[email address]>
Sent: Tuesday, 22 September 2020 11:45 AM
To: Tony Vujnovich <
[email address]>
Cc: Kirsten Taylor <
[email address]>
Subject: SleepDrops International Callaghan Funding Grant
Hi Tony-
Great timing with your call this morning thank you- I have sent a meeting invite for this Thursday at our offices 2 pm.
By way of introduction please review the links to our website and the following high level detail of funding
requirements.
https://sleepdrops.co.nz/
https://sleepdrops.co.nz/our-team/
SleepDrops is a manufacturer of natural sleep supplements. We are an award winning company (NZ number one
sleep category with pharmacies and supermarkets) specialising in the sleep category in the retail, wholesale and
practitioner markets of NZ, Australia and the US. We have an aggressive growth strategy to expand export markets.
We will discuss this strategy at our initial meeting.
SleepDrops international is looking for funding assistance from Callaghan for the following initiatives:
1. New product development
2. Clinical trials as a means to develop and expand into new markets with an initial focus on USA and Australia.
We have already completed and been approved from a Regulatory perspective for Export expansion into these
markets (TGA,FDA)
1-
SleepDrops International is looking to develop a new formulation that meets the needs of a large niche within the
natural health sector. We need the formula to be highly effective and safe as well as licensable/patentable. We need
to have clinical trials to prove efficacy.
The product is to be a natural health supplement utilising natural ingredients which are scientifically researched for
pain relief but combined in a unique way. We want to develop this product specifically for people who have physical
pain issues such as those following an injury, a fall, a car accident. These people will be visiting a practitioner for
treatment and will be needing support for this pain and recovery.
As a natural health company that specialises in sleep we realise that pain is one of the main barriers to people
experiencing insomnia and we see this as an area that is not being addressed within the retail and practitioner sector.
With 27,000 allied practitioners in NZ alone we see this as an important area to develop and scientifically trial this
product which can then be marketed to other practitioners around the world. Estimated cost of product development
circa $90k (TBC)
Released
2-
We are looking to commission the AUT research department or Callaghan Innovation and commission 3 clinical
trials at a cost or circa . Trials will establish the following results:
Pain relief product with specific manufacturing processes that makes the product highly effective, unique and
patentable.
Scientific evidence to meet regulatory requirements for specific markets such as Korea, Japan and China.
Estimated cost TBC but estimated in the 100k region.
under the Official Information Act 1982
Regards
Mark
Mark Olley
General Manager
SleepDrops International
1/75 Ellice Road, Wairau Valley, Auckland, New Zealand
9(2)(a) - Privacy
www.SleepDrops.co.nz
Notice of Confidential Information:
This message is for the named person's use only. It may contain confidential, proprietary or legally privileged information. No confidentiality or privilege
is waived or lost by any mistransmission. If you receive this message in error, please immediately delete it and all copies of it from your system, destroy
any hard copies of it and notify the sender. You must not, directly or indirectly, use, disclose, distribute, print, or copy any part of this message if you are
Released
not the intended recipient.
Thank You.
P Please consider your environmental responsibilities before printing this e-mail
under the Official Information Act 1982
CAUTION: This email message and any attachments contain information that may be confidential and
may be LEGALLY PRIVILEGED. If you are not the intended recipient, any use, disclosure or copying
of this message or attachments is strictly prohibited. If you have received this email message in error
please notify us immediately and erase all copies of the message and attachments. We do not accept
responsibility for any viruses or similar carried with our email, or any effects our email may have on the
recipient computer system or network. Any views expressed in this email may be those of the individual
sender and may not necessarily reflect the views of Auckland Tourism, Events and Economic
Development Ltd.
Mark Olley <[email address]>
9 October 2020 at 08:44
To: Tony Vujnovich <[email address]>
Cc: Mark Robinson <[email address]>
Hi Tony and Mark
I’m new to the company so I’m not sure as to what communication has been made in the past.
Mark are you available for a quick call today?
[Quoted text hidden]
1- New product development
2-
Clinical trials as a means to develop and expand into new markets with an initial focus on USA and
Australia. We have already completed and been approved from a Regulatory perspective for Export
expansion into these markets (TGA,FDA)
[Quoted text hidden]
